Pharmacoeconomic review report Dexamethasone (Ozurdex) (Allergan Inc.)
Dexamethasone intravitreal implant (Ozurdex) is a glucocorticoid receptor agonist that targets angiogenic vascular-endothelial growth factor (VEGF) and pro-inflammatory pathways of diabetic macular edema (DME). It received a Health Canada notice of compliance on April 16, 2015 for the treatment of D...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
CADTH
2018.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270406719 |
